Myocardial damage after successful thrombolysis is associated with the duration of ST re-elevation at reperfusion

Clin Cardiol. 1995 Jun;18(6):324-8. doi: 10.1002/clc.4960180607.

Abstract

The purpose of this study was to investigate the significance of ST re-elevation at reperfusion using strict criteria for patient inclusion and exclusion. Twenty-nine patients who had a first anterior infarction with single-vessel disease, successful recanalization by intracoronary thrombolysis (ICT) with urokinase, and an angiographically confirmed patent infarct-related artery after 4 weeks, were divided into three groups according to the deviation of the ST segment at reperfusion: Group A, 10 patients with sustained ST re-elevation; Group B, 10 patients with transient ST re-elevation; and Group C, 9 patients with ST reduction. Left ventricular (LV) function was evaluated from cineventriculograms performed in the 30 degrees right anterior projection 4 weeks after ICT. LV ejection fraction and regional wall motion of the infarct area, evaluated by the centerline method (SD/chords), were significantly lower in Group A (44 +/- 10%, -3.2 +/- 0.4) than in Group B (61 +/- 9%, -1.9 +/- 0.7) and Group C (60 +/- 5%, -2.0 +/- 0.4) (p < 0.01). Peak creatine kinase (CK) activity was significantly higher in Group A (5848 +/- 2112 IU) than in Group B (2485 +/- 1254 IU) and Group C (1889 +/- 1525 IU) (p < 0.05). These data suggest that a sustained ST re-elevation at reperfusion was strongly associated with marked LV dysfunction and higher peak CK activity. It was concluded that sustained, not transient, ST re-elevation associated with successful reperfusion indicates extensive myocardial damage.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Analysis of Variance
  • Coronary Angiography
  • Creatine Kinase / analysis
  • Electrocardiography
  • Female
  • Humans
  • Isoenzymes
  • Male
  • Middle Aged
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / physiopathology
  • Myocardial Reperfusion
  • Myocardial Reperfusion Injury / physiopathology*
  • Prognosis
  • Retrospective Studies
  • Thrombolytic Therapy* / methods
  • Urokinase-Type Plasminogen Activator / administration & dosage
  • Urokinase-Type Plasminogen Activator / therapeutic use*
  • Ventricular Function, Left / drug effects
  • Ventricular Function, Left / physiology

Substances

  • Isoenzymes
  • Creatine Kinase
  • Urokinase-Type Plasminogen Activator